Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
Ermelinda De Maio(Azienda Usl Toscana Centro), A. De Matteis(Università Cattolica del Sacro Cuore), Federica Perrone(University of Bari Aldo Moro), V. Labonia, Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Staiano(Tumour Institute of Tuscany), Massimiliano D’Aiuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Franca La Vecchia(Tumour Institute of Tuscany), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Emanuela Rossi(University of Milan), Francesca Di Rella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), P Silvestro, Maria Pia Curcio(Tumour Institute of Tuscany), Carmen Pacilio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Franca Formichelli(Tumour Institute of Tuscany), Nicola Maurea(Cancer Institute (WIA)), Maurizio Di Bonito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gabriella Landi, Giuseppe D’Aiuto(Memorial Sloan Kettering Cancer Center), Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Renato Thomas(Tumour Institute of Tuscany), Giuseppe Signoriello(University of Naples Federico II)
Cited by 26
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries
|JAMA|2021|649
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460